Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Official Title

A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients With Relapsed/Refractory Cancer Indications

Summary:

This is a first-in-human, multi-centre, open-label clinical study with separate dose escalation (Phase 1) and expansion (Phase 2) stages to assess preliminary safety, tolerability, and efficacy of the second generation oral XPO1 inhibitor KPT-8602 in participants with relapsed/refractory multiple myeloma (MM), metastatic colorectal cancer (mCRC), metastatic castration resistant prostate cancer (mCRPC), and higher risk myelodysplastic syndrome (HR-MDS). Dose escalation and dose expansion may be included for all parts of the study as determined by ongoing study results.

Trial Description

Primary Outcome:

  • Part A1, A2, B, C, D, E, F: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
  • Part A1, A2, B, C, D, E, F: Overall Response Rate (ORR)
  • Part A1, A2, B, C, D, E, F: Duration of Response (DOR)
  • Part A1, A2, B, C, D, E, F: Progression-free survival (PFS)
  • Part A1, A2, B, C, D, E, F: Overall Survival (OS)
  • Part A1, A2, B, C, D, E, F: Clinical Benefit Rate (CBR)
  • Part A1, A2, B, C, D, E, F: Duration of Clinical Benefit Rate (CBR)
  • Part A1, A2, B, C, D, E, F: Disease control rate (DCR)
  • Part A1, A2, B, C, D, E, F: Duration of DCR
  • Part F Phase 2: ORR
  • Part G: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
  • Part H: 2- Year Progression-free Survival (PFS)
Secondary Outcome:
  • Part A1, A2, B, C, D, E, F, H: Area Under the Plasma Concentration Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Eltanexor
  • Part A1, A2, B, C, D, E, F, H: Maximum Observed Plasma Concentration (Cmax) of Eltanexor
  • Part A1, A2, B, C, D, E, F, H: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Eltanexor
  • Part A1, A2, B, C, D, E, F, H: Apparent Terminal Half Life (t1/2) of Eltanexor
  • Part A1, A2, B, C, D, E, F, H: Apparent Total Body Clearance Eltanexor
  • Part A1, A2, B, C, D, E, F, H: Apparent Volume of Distribution During Terminal Phase (VZ/f) of Eltanexor
  • Part F Phase 2: Overall Survival (OS)
  • Part F Phase 2: 6-Month Overall Survival (OS)
  • Part F Phase 2: Progression-free survival (PFS)
  • Part F Phase 2: Disease control rate (DCR)
  • Part F Phase 2: Duration of Response (DOR)
  • Part F Phase 2: Rate of Conversion from Red Blood Cell (RBC) Transfusion Dependence to Independence
  • Part F Phase 2: Rate of Conversion from Platelet Transfusion Dependence to Independence
  • Part G: Overall Response Rate (ORR)
  • Part G: Duration of Response (DOR)
  • Part H: Rate of Minimal Residual Disease (MRD) Conversion from Positive to Negative
  • Part H: Time to Minimal Residual Disease (MRD) Negativity
  • Part H: Percentage of Participants with Acute and Chronic Graft-versus-Host Disease (GVHD)
  • Part H: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
  • Part H: Overall Survival (OS)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society